ClinicalTrials.gg
RecruitingNCT07403084NEMOST V2Updated Feb 11, 2026

Post-market Clinical Follow-up Study of NEMOST V2

An interventional study of NEMOST V2 growing domino in Scoliosis Neuromuscular, Scoliosis Idiopathic and Consent Forms, sponsored by EUROS. Recruiting at 5 sites in France. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by EUROS · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Scoliosis with a site in France — 18 open to participants now, 20 under way, 1 of them phase 3. Scoliosis · France.

Planned enrollment
6th of 25
140 · median 60
Started
2025
with 4 others
No phase
24 of 57
11 open now
Primary completion
2033-12
later than 19 of 19 live
Registered
53rd of 57
by date

Among the 57 studies in Scoliosis with a site in France, this one is the 6th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2025, is one of 24 with no phase, reaches primary completion later than 19 of the 19 other live ones, and was the 53rd registered.

Scoliosis

660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.

Browse Scoliosis studies →

Open to participants now

18 of the 57 studies in Scoliosis with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Scoliosis with a site in France, or all of them as a file.
02

Study summary

The NEMOST spinal implant is a growth domino intended for the surgical treatment of progressive scoliosis in children.

As part of post-market surveillance, EUROS is conducting a retrospective and prospective study to collect clinical and radiological data on the NEMOST growth domino.

Retrospective and prospective multicenter post-market surveillance clinical study.

This study is interventional, non-randomized, and uncontrolled. The primary objective of this clinical study is to monitor complications related to the NEMOST growth domino during a 5-year postoperative follow-up in patients treated for progressive scoliosis in children.

The secondary objective of this clinical study is to monitor the performance of the NEMOST growth domino during a 5-year postoperative follow-up in patients treated for progressive scoliosis in children.

The study will include 140 patients.

03

Conditions studied

  • Scoliosis Neuromuscular
  • Scoliosis Idiopathic
  • Consent Forms

Browse trials for

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic, congenital, neuromuscular, or syndromic scoliosis : Progressive spinal deformity not managed by orthopedic treatment, and requiring primary surgical intervention.
  • The patient, as well as their parents or legal guardians, are informed of the participation in the study.
  • Patients aged from 5 to 17 yeas old, excepted the one who still have a potential for growth

Exclusion criteria

Exclusion Criteria:

  • signs of local inflammation;
  • acute or chronic, local or systemic infections ;
  • non-reducible scoliosis ;
  • pathological obesity ;
  • allergy or intolerance to implanted materials;
  • insufficiency or absence of tissue coverage. The NEMOST implant should not be used in a spine that has already been instrumented or fused.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    NEMOST V2

    Device: NEMOST V2 growing domino

Interventions

  • DeviceNEMOST V2 growing domino

    The NEMOST spinal implant is a growth domino intended for the surgical treatment of progressive scoliosis in children.

06

What researchers measure

Primary outcomes

  1. Complication rate

    The safety of the device will be studied by monitoring all complications, reinterventions and revisions.

    Time frame: 5 years

Secondary outcomes

  1. Cobb angle (°)

    Comparison between preoperative measures, immediate postoperative measures and each visit measures. Measured on seated or standing anteroposterior and lateral X-ray images by identifying the most tilted vertebrae at the top and bottom of the spinal curve, drawing lines along their endplates, and calculating the angle formed by the intersection of perpendiculars to these lines. Normal value for Cobb angle is \<10° for no or benign scoliosis, medium scoliosis is defined between 15 and 35°, important scoliosis is defined as between 35 and 60° and very important scoliosis corresponds to angle \> 65°. The Cobb angle correction, used to compare pre and postoperative angle is defined as 100\*(preoperative value - postoperative value) / postoperative value.

    Time frame: 5 years

  2. Early-Onset Scoliosis questionnaire 24 items (EOSQ-24)

    Considering clinical evaluation, the EOSQ-24 auto questionnaire addressed to patients' parents was selected. The 24-Item Early-onset Scoliosis Questionnaire (EOSQ-24) is a locally validated measurement tool to evaluate the overall impact of early onset scoliosis on patients' physical, psychological, and socio-economic well-being. Clinical results are assessed thanks to the EOSQ-24 quality of life questionnaire. It is divided in 11 themes, for which a score is calculated over 100. Each item is composed of 1 to 5 questions rated from 1 to 5, 5 being the best score. These scores will be between 0 to 100. Comparison between preoperative measures, immediate postoperative measures and each visit measures.

    Time frame: 5 years

  3. Pelvic obliquity (°)

    Measured on seated or standing anteroposterior and lateral X-ray images by drawing a line between the iliac crests (or the inferior aspects of the sacroiliac joints) and calculating the angle between this line and a horizontal reference line. Normal value is 0°. Comparison between preoperative measures, immediate postoperative measures and each visit measures.

    Time frame: 5 years

  4. Thoracic kyphosis (°)

    Measured on seated or standing anteroposterior and lateral X-ray images by calculating the Cobb angle between the superior endplate of the upper thoracic vertebra and the inferior endplate of the lower thoracic vertebra defining the kyphotic curve (commonly T4-T12). Comparison between preoperative measures, immediate postoperative measures and each visit measures.

    Time frame: 5 years

  5. Lumbar lordosis (°)

    Measured on seated or standing anteroposterior and lateral X-ray images by calculating the Cobb angle between the superior endplate of the upper lumbar vertebra and the superior endplate of the sacrum (commonly L1-S1). Comparison between preoperative measures, immediate postoperative measures and each visit measures. Normal value ranges from 20 to 60°.

    Time frame: 5 years

  6. T1-T12 and T1-S1 length (mm)

    T1-T12 length is measured on a standing or seated anteroposterior spinal radiograph as the linear distance between the midpoint of the superior endplate of T1 and the midpoint of the inferior endplate of T12. T1-S1 length is measured on a standing or seated anteroposterior spinal radiograph as the linear distance between the midpoint of the superior endplate of T1 and the midpoint of the superior endplate of S1. Comparison between preoperative measures, immediate postoperative measures and each visit measures.

    Time frame: 5 years

  7. Respiratory functional exploration

    Pulmonary function testing is performed in a seated or supine position by measuring Total Lung Capacity (TLC, mL) and Vital Capacity (VC, mL) using standardized pulmonary function tests. Comparison between preoperative measures and each visit measures.

    Time frame: 5 years

07

Study locations

2 of 5 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2033, 96 months after the start.

Of 234 interventional studies with no phase under Scoliosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 96 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 11, 2026
StartActual
Dec 19, 2025
Primary completionEst.
Dec 19, 2033
CompletionEst.
Dec 19, 2033
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07403084
Lead sponsor
EUROS
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Dec 19, 2025
Primary completion
Dec 19, 2033 (estimated)
Completion
Dec 19, 2033 (estimated)
Last update
Feb 11, 2026

Study contacts

Célia Armanet, PHD
Contact
carmanet@euros.fr
+330756848896
Federico Solla, MD
principal investigator · Centre Hospitalier Universitaire de Nice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion